Marubi(603983)2022-08-26 16:00Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥817.18 million, a decrease of 6.48% compared to ¥873.80 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥117.07 million, down 38.11% from ¥189.15 million in the previous year[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥100.85 million, a decrease of 36.57% compared to ¥158.98 million in the same period last year[21]. - Basic earnings per share for the first half of 2022 were ¥0.29, down 38.30% from ¥0.47 in the same period last year[21]. - The company achieved a revenue of 817 million, a year-on-year decrease of 6.48%, with an overall gross margin of 69.21%, an increase of 5.14 percentage points[34]. - The net profit attributable to shareholders was 117 million, a year-on-year decrease of 38.11%, while the net profit after deducting non-recurring gains and losses was 101 million, down 36.57%[34]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a 25% year-over-year growth[100]. - The company reported a total comprehensive income of CNY -76.3 million for the period[177]. - The total equity at the end of the period reached 2,533,911,145.91 RMB, with a notable increase in retained earnings of 1,168,181,531.45 RMB[193]. Cash Flow and Assets - The net cash flow from operating activities increased to approximately ¥13.08 million, compared to a negative cash flow of ¥42.51 million in the same period last year[21]. - Cash and cash equivalents increased by 22.16% to approximately 984.76 million, accounting for 25.78% of total assets[51]. - Inventory decreased by 10.77% to approximately 123.51 million, representing 3.23% of total assets[51]. - The company reported a significant increase of 47.85% in construction in progress, totaling approximately 175.37 million, due to new factory and office building projects[51]. - The total assets at the end of the reporting period were approximately ¥3.82 billion, an increase of 1.56% from ¥3.76 billion at the end of the previous year[21]. - The company reported cash outflow from investment activities of CNY 482,600,879.00, a decrease from CNY 1,262,649,817.16 in the previous year[164]. - The total liabilities reached ¥624,588,101.25, an increase from ¥603,185,131.96, which is a growth of around 3.67%[141]. Research and Development - Research and development expenses amounted to 24.64 million, maintaining a consistent investment level[34]. - The company focuses on technological innovation, advancing research in gene engineering, biological fermentation, and plant extraction[37]. - The company has expanded its partnerships with three universities for research projects, enhancing its R&D capabilities[37]. - The company applied for 34 new patents, including 31 invention patents and 3 utility model patents, and received 39 new patent authorizations, including 35 invention patents[40]. - The company is investing 200 million yuan in research and development for new technologies aimed at enhancing product efficiency[104]. Market and Competition - The cosmetics industry faced challenges, with retail sales of cosmetics declining by 2.5% in the first half of 2022[28]. - The company faced intensified market competition in the cosmetics industry, necessitating continuous product innovation and brand building[58]. - The company is actively adjusting its product structure and implementing cost control measures to mitigate the impact of rising raw material and labor costs[36]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for potential deals[106]. Corporate Governance and Compliance - The company reported no profit distribution plan or capital reserve transfer plan for the reporting period[6]. - The company completed the repurchase and cancellation of restricted stock on July 7, 2022, as part of its stock incentive plan[67]. - The company committed to not transferring benefits to other entities or individuals without fair conditions, ensuring the protection of investor interests[95]. - The company will ensure that any share reduction complies with the Shanghai Stock Exchange rules and relevant laws[80]. - The company emphasizes the importance of maintaining compliance with legal and regulatory requirements in its stock repurchase and stabilization efforts[88]. Strategic Initiatives - The company is focusing on optimizing supply chain processes and reducing costs to improve efficiency, which contributed to the positive cash flow from operating activities[21]. - The company has established a complete supply chain system for raw material procurement, sourcing from international manufacturers such as BASF and Dow[30]. - The company has established partnerships with multiple universities and research institutions, leading to the initiation of key R&D projects in green bio-manufacturing[38]. - The company is enhancing its digital capabilities by integrating data across various online platforms, improving decision-making for new product development and marketing strategies[44]. Shareholder Information - The company’s major shareholders have committed to not transferring shares for 36 months post-IPO and have outlined specific conditions for any future share reductions[77]. - The company holds 15% of its shares, with a reduction period of six months from the announcement of the reduction plan[80]. - The company will implement stock buyback measures if the stock price stabilization conditions are triggered, with a maximum of 20% of the previous year's net profit allocated for buybacks[82]. - The company will not transfer shares for six months following any violation of share reduction commitments[80].